Elutia to Present at Global BioInnovation Forum on NXT-41x Biomatrix Program for Plastic and Reconstructive Surgery
Rhea-AI Summary
Elutia (Nasdaq: ELUT) will present at the Virtual Global BioInnovation Forum during the JP Morgan Healthcare Conference on Jan 13, 2026 at 10:00 a.m. PT / 1:00 p.m. ET. The company will highlight progress on NXT-41x, a next-generation antibiotic-eluting biomatrix for plastic and reconstructive surgery that builds on Elutia's validated biomatrix platform.
Presentation speakers are Randy Mills, PhD, CEO of Elutia, and Christopher Reid, MD, a plastic surgeon and researcher from UC San Diego Health, who will discuss unmet needs in breast reconstruction, including postoperative infection rates up to 25% and serious complication rates affecting one in three patients. A live and archived webcast will be available in the Investors section at investors.elutia.com.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ELUT gained 4.71%, reflecting a moderate positive market reaction. Argus tracked a peak move of +7.5% during that session. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $33M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ELUT gained 3.76% while peers were mixed: SRTS up 2.31%, WOK up 10.28%, but CTSO, MDAI, and TELA fell between 2.68% and 4.79%, pointing to stock-specific dynamics rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 06 | Earnings and divestiture | Positive | -5.0% | Q3 2025 results and BioEnvelope sale proceeds to fund NXT-41x. |
| Oct 23 | Earnings scheduling | Neutral | -0.7% | Announcement of Q3 2025 results release date and conference call. |
| Oct 14 | Investor conference | Neutral | +0.9% | CEO presentation and 1x1 meetings at LD Micro Main Event XIX. |
| Oct 10 | Board appointment | Positive | +0.8% | Appointment of experienced medtech executive to support transformation. |
| Oct 01 | Asset sale | Positive | -0.6% | Closing of $88M BioEnvelope sale and refocus on NXT-41x platform. |
Recent positive strategic and financial updates have sometimes seen negative or muted price reactions, suggesting occasional divergence between news tone and short-term trading.
Over the last few months, Elutia has reshaped its business around the NXT-41x drug‑eluting biomatrix platform. It closed the sale of its BioEnvelope business to Boston Scientific for $88 million on Oct 1, 2025, then reported Q3 2025 results showing $3.3M in net sales and improved 55.8% gross margin. Governance and visibility steps included adding an experienced medtech director and multiple conference appearances. Today’s Global BioInnovation Forum presentation continues this focus on NXT-41x and breast reconstruction complications.
Market Pulse Summary
This announcement emphasizes Elutia’s participation in the Global BioInnovation Forum to highlight progress on NXT-41x, an antibiotic‑eluting biomatrix for breast reconstruction. The presentation underscores high complication and infection rates, supporting the rationale for local antibiotic delivery. In the past six months, Elutia has sold its BioEnvelope business and refocused on this platform. Investors may watch upcoming NXT-41x clinical milestones, commercialization timelines, and further updates shared via webcasts and conferences to gauge how the program advances.
Key Terms
drug-eluting biomatrix medical
biomatrix medical
microsurgery medical
postoperative medical
local antibiotic delivery medical
AI-generated analysis. Not financial advice.
Company to present Tuesday, January 13th at 10:00 a.m. PT / 1:00 p.m. ET
GAITHERSBURG, Md., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced its participation in the inaugural Global BioInnovation Forum, taking place virtually during the JP Morgan Healthcare Conference on January 13, 2026.
Elutia will highlight progress in its NXT-41x program, a next-generation antibiotic-eluting biomatrix for use in plastic and reconstructive surgery. NXT-41x builds on the Company’s validated biomatrix technology platform, which has been clinically and commercially established through prior antibiotic-eluting products. Elutia believes this platform is well positioned to address persistent unmet needs in breast reconstruction.
Randy Mills, PhD, Chief Executive Officer of Elutia, will present alongside Christopher Reid, MD, Associate Professor of Surgery at UC San Diego Health. Dr. Reid is a plastic surgeon with expertise in microsurgery and complex breast reconstruction, and he is at the forefront of research efforts to address postoperative complications, including infection risk. He has published research on successful strategies to reduce complications, including the benefits of local antibiotic delivery.
Dr. Reid will highlight the urgent unmet medical need for patients undergoing breast reconstruction, which carries a postoperative infectious complication rate of up to
The virtual presentation will take place on Tuesday, January 13, 2026, at 10:00 a.m. PT (1:00 p.m. ET). The Global BioInnovation Forum brings together leaders across biotechnology, digital health, and life sciences to discuss innovations shaping the future of healthcare.
A live and archived webcast of the event will be available on the “Investors” section of the Elutia website at http://investors.elutia.com/.
About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including any statements and information concerning NXT-41x and expectations for its FDA clearance and its potential to address unmet clinical needs in the breast reduction market. These forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to us. Such beliefs and assumptions may or may not prove to be correct. Additionally, such forward-looking statements are subject to a number of known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied in the forward-looking statements, including, but not limited to the following: our ability to enhance our products, expand our product indications and develop, acquire and commercialize additional product offerings, including NXT-41 and NXT-41x; our ability to obtain regulatory approval or other marketing authorizations by the U.S. Food and Drug Administration and comparable foreign authorities for our products and product candidates, including NXT-41 and NXT-41x; our ability to achieve or sustain profitability; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; the risk of product liability claims and our ability to obtain or maintain adequate product liability insurance; our ability to defend against the various lawsuits related to FiberCel and other viable bone matrix products and avoid a material adverse financial consequence; our ability to raise funds in the future in the amounts and at the times needed; the continued and future acceptance of our products by the medical community; our dependence on independent sales agents to generate a substantial portion of our net sales; our dependence on a limited number of third-party suppliers and manufacturers, which, in certain cases are exclusive suppliers for products essential to our business; our ability to successfully realize the anticipated benefits of the October 2025 sale of our CIED business and the November 2023 sale of our Orthobiologics business; physician awareness of the distinctive characteristics, benefits, safety, clinical efficacy and cost-effectiveness of our products; our ability to compete against other companies, most of which have longer operating histories, more established products and/or greater resources than we do; pricing pressure as a result of cost-containment efforts of our customers, purchasing groups, third-party payors and governmental organizations could adversely affect our sales and profitability; our ability to obtain, maintain and adequately protect our intellectual property rights.; and other important factors which can be found in the “Risk Factors” section of Elutia’s public filings with the Securities and Exchange Commission (“SEC”), including Elutia’s Annual Report on Form 10-K for the year ended December 31, 2024, as such factors may be updated from time to time in Elutia’s other filings with the SEC, including Elutia’s Quarterly Reports on Form 10-Q, accessible on the SEC’s website at www.sec.gov and the Investor Relations page of Elutia’s website at https://investors.elutia.com. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. Any forward-looking statement made by Elutia in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, Elutia expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Investors:
David Carey
FINN Partners
david.carey@finnpartners.com
FAQ
When will Elutia (ELUT) present on NXT-41x at the Global BioInnovation Forum?
What is NXT-41x that Elutia (ELUT) will discuss on Jan 13, 2026?
Who will speak for Elutia (ELUT) about NXT-41x at the forum?
What clinical risks in breast reconstruction will be addressed in the Elutia (ELUT) presentation?
How can investors watch Elutia's (ELUT) Global BioInnovation Forum presentation?
